Scroll

vilazodone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4223	163521-12-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vilazodone viibryd vilazodone hydrochloride vilazodone HCl	A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT. Molecular weight: 441.54 Formula: C26H27N5O2 CLOGP: 4.33 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 102.29 ALOGS: -3.56 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vilazodone
viibryd
vilazodone hydrochloride
vilazodone HCl

A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT.

Molecular weight: 441.54
Formula: C26H27N5O2
CLOGP: 4.33
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 102.29
ALOGS: -3.56
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	4.85 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.76 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.03 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	15.66 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 21, 2011	FDA	FOREST LABS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	255.28	20.04	122	5843	62299	63420758
Abnormal dreams	143.47	20.04	49	5916	10467	63472590
Hallucination	123.44	20.04	72	5893	54745	63428312
Persistent genital arousal disorder	99.18	20.04	18	5947	268	63482789
Anxiety	94.56	20.04	109	5856	217432	63265625
Serotonin syndrome	90.23	20.04	47	5918	28635	63454422
Agitation	80.95	20.04	57	5908	59700	63423357
Nightmare	76.70	20.04	37	5928	19157	63463900
Sleep paralysis	72.93	20.04	16	5949	644	63482413
Mania	68.77	20.04	30	5935	12337	63470720
Paraesthesia	62.04	20.04	75	5890	156891	63326166
Completed suicide	56.57	20.04	69	5896	145604	63337453
Insomnia	56.18	20.04	84	5881	215168	63267889
Anger	55.84	20.04	26	5939	12430	63470627
Crying	50.73	20.04	30	5935	23313	63459744
Suicide attempt	47.54	20.04	42	5923	60876	63422181
Tremor	47.10	20.04	60	5905	132179	63350878
Irritability	47.04	20.04	32	5933	31662	63451395
Feeling abnormal	46.16	20.04	63	5902	148329	63334728
Seizure	42.29	20.04	57	5908	132577	63350480
Dizziness	42.02	20.04	111	5854	429814	63053243
Depression	41.98	20.04	70	5895	196422	63286635
Tardive dyskinesia	35.81	20.04	17	5948	8485	63474572
Withdrawal syndrome	34.04	20.04	22	5943	19975	63463082
Muscle twitching	31.92	20.04	21	5944	19647	63463410
Dissociation	29.89	20.04	11	5954	2908	63480149
Electric shock sensation	29.54	20.04	8	5957	780	63482277
Panic attack	29.50	20.04	21	5944	22310	63460747
Nausea	25.10	20.04	151	5814	854320	62628737
Obsessive-compulsive disorder	23.05	20.04	10	5955	4050	63479007
Hypnagogic hallucination	22.97	20.04	5	5960	194	63482863
Diarrhoea	22.64	20.04	129	5836	715237	62767820
Homeless	21.17	20.04	4	5961	75	63482982

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	142.18	33.14	61	1928	40327	34914615
Serotonin syndrome	141.05	33.14	50	1939	19883	34935059
Completed suicide	91.20	33.14	61	1928	98107	34856835
Mania	52.83	33.14	20	1969	9491	34945451
Sexual dysfunction	49.03	33.14	17	1972	6286	34948656
Anxiety	40.30	33.14	38	1951	99390	34855552
Overdose	35.36	33.14	34	1955	91025	34863917
Irritability	34.61	33.14	20	1969	24670	34930272

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	213.97	21.28	105	5475	76235	79662573
Serotonin syndrome	138.28	21.28	66	5514	44961	79693847
Completed suicide	125.44	21.28	117	5463	245650	79493158
Persistent genital arousal disorder	98.00	21.28	17	5563	264	79738544
Abnormal dreams	94.44	21.28	34	5546	11378	79727430
Anxiety	85.96	21.28	96	5484	248416	79490392
Hallucination	66.48	21.28	52	5528	85693	79653115
Mania	66.04	21.28	30	5550	18230	79720578
Anger	58.31	21.28	27	5553	17135	79721673
Irritability	55.40	21.28	35	5545	41109	79697699
Sleep paralysis	55.19	21.28	12	5568	626	79738182
Nightmare	53.33	21.28	29	5551	25832	79712976
Tremor	50.81	21.28	61	5519	170022	79568786
Crying	50.76	21.28	27	5553	23016	79715792
Insomnia	50.15	21.28	73	5507	245097	79493711
Paraesthesia	45.86	21.28	59	5521	176264	79562544
Agitation	44.13	21.28	44	5536	99671	79639137
Suicide attempt	37.43	21.28	37	5543	82895	79655913
Intentional overdose	36.63	21.28	41	5539	105919	79632889
Muscle twitching	33.16	21.28	21	5559	24743	79714065
Depression	32.46	21.28	56	5524	216734	79522074
Feeling abnormal	30.48	21.28	46	5534	159153	79579655
Tardive dyskinesia	27.92	21.28	14	5566	10557	79728251
Dizziness	27.49	21.28	90	5490	526351	79212457
Off label use	27.07	21.28	130	5450	907085	78831723
Dissociation	26.00	21.28	10	5570	4011	79734797
Memory impairment	25.35	21.28	35	5545	111699	79627109
Withdrawal syndrome	24.58	21.28	18	5562	26836	79711972
Product substitution issue	24.22	21.28	16	5564	20240	79718568
Seizure	23.45	21.28	45	5535	188789	79550019
Obsessive-compulsive disorder	22.25	21.28	10	5570	5917	79732891
Panic attack	21.64	21.28	16	5564	24200	79714608

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AX24	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D017367	Selective Serotonin Reuptake Inhibitors
MeSH PA	D058825	Serotonin 5-HT1 Receptor Agonists
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017366	Serotonin Receptor Agonists
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35941	serotonin agonists
CHEBI has role	CHEBI:50949	SSRI

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Major depressive disorder	indication	370143000
Suicidal thoughts	contraindication	6471006
Bipolar disorder	contraindication	13746004	DOID:3312
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hyponatremia	contraindication	89627008
Seizure disorder	contraindication	128613002
Suicidal	contraindication	267073005
Serotonin syndrome	contraindication	371089000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.56	acidic
pKa2	13.13	acidic
pKa3	8.58	Basic
pKa4	1.41	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	Jan. 31, 2023	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
20MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	Jan. 31, 2023	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
40MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	Jan. 31, 2023	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
10MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	July 31, 2023	PEDIATRIC EXCLUSIVITY
20MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	July 31, 2023	PEDIATRIC EXCLUSIVITY
40MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	July 31, 2023	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	IC50	9.30	IUPHAR	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	AGONIST	Ki	9.70	IUPHAR	CHEMBL
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	5.41	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	IC50	7.15	IUPHAR
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	AGONIST	IC50	6.50	IUPHAR
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		IC50	6.53	CHEMBL
5-hydroxytryptamine receptor 4	GPCR	Q13639	5HT4R_HUMAN	AGONIST	IC50	6.60	IUPHAR
Adrenergic receptor alpha-2	GPCR	P08913 P18089 P18825	ADA2A_HUMAN ADA2B_HUMAN ADA2C_HUMAN		IC50	5.22	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	IC50	6.18	IUPHAR
Adrenergic receptor alpha-1	GPCR	P25100 P35348 P35368	ADA1D_HUMAN ADA1A_HUMAN ADA1B_HUMAN		IC50	5.70	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		IC50	6.80	CHEMBL
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		IC50	5.30	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		IC50	6.18	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	9.52	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		IC50	9.30	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		IC50	5.82	CHEMBL
Acetylcholinesterase	Enzyme		ACES_MOUSE		IC50	4.67	CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT		IC50	5.52	CHEMBL
Acetylcholinesterase	Enzyme		ACES_RAT		IC50	4.67	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT		IC50	5.70	CHEMBL
5-hydroxytryptamine receptor 4	GPCR		5HT4R_RAT		IC50	6.60	CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		IC50	7.15	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR		5HT1D_RAT		IC50	5.40	CHEMBL
D(4) dopamine receptor	GPCR		DRD4_RAT		IC50	5.47	CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT		IC50	5.52	CHEMBL
Serotonin 3 (5-HT3) receptor	Ion channel		5HT3A_RAT 5HT3B_RAT		IC50	5.37	CHEMBL

External reference:

ID	Source
4030483	VUID
N0000182438	NUI
D09698	KEGG_DRUG
163521-08-2	SECONDARY_CAS_RN
4030483	VANDF
4030484	VANDF
C1530072	UMLSCUI
CHEBI:70707	CHEBI
CHEMBL439849	ChEMBL_ID
CHEMBL1615374	ChEMBL_ID
D000069503	MESH_DESCRIPTOR_UI
DB06684	DRUGBANK_ID
7427	IUPHAR_LIGAND_ID
7638	INN_ID
S239O2OOV3	UNII
6918314	PUBCHEM_CID
1086768	RXNORM
179494	MMSL
27744	MMSL
359491	MMSL
d07740	MMSL
013753	NDDF
013754	NDDF
702837008	SNOMEDCT_US
702838003	SNOMEDCT_US
715638004	SNOMEDCT_US
YG7	PDB_CHEM_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1110	TABLET	10 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1110	TABLET	10 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1120	TABLET	20 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1120	TABLET	20 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1140	TABLET	40 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1140	TABLET	40 mg	ORAL	NDA	32 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0480-2043	TABLET, FILM COATED	40 mg	ORAL	ANDA	29 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0480-2044	TABLET, FILM COATED	20 mg	ORAL	ANDA	29 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0480-2045	TABLET, FILM COATED	10 mg	ORAL	ANDA	29 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-352	TABLET	10 mg	ORAL	ANDA	33 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-352	TABLET	10 mg	ORAL	ANDA	33 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-353	TABLET	20 mg	ORAL	ANDA	33 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-353	TABLET	20 mg	ORAL	ANDA	33 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-354	TABLET	40 mg	ORAL	ANDA	33 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-354	TABLET	40 mg	ORAL	ANDA	33 sections
VILAZODONE HYDROCHLORIDE	Human Prescription Drug Label	1	46708-232	TABLET, FILM COATED	10 mg	ORAL	ANDA	31 sections
VILAZODONE HYDROCHLORIDE	Human Prescription Drug Label	1	46708-233	TABLET, FILM COATED	20 mg	ORAL	ANDA	31 sections
VILAZODONE HYDROCHLORIDE	Human Prescription Drug Label	1	46708-234	TABLET, FILM COATED	40 mg	ORAL	ANDA	31 sections
vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	51407-691	TABLET	10 mg	ORAL	NDA authorized generic	31 sections
vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	51407-691	TABLET	10 mg	ORAL	NDA authorized generic	31 sections
Vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	51407-692	TABLET	20 mg	ORAL	NDA authorized generic	31 sections
Vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	51407-692	TABLET	20 mg	ORAL	NDA authorized generic	31 sections
Vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	51407-693	TABLET	40 mg	ORAL	NDA authorized generic	31 sections
Vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	51407-693	TABLET	40 mg	ORAL	NDA authorized generic	31 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4624	TABLET	40 mg	ORAL	NDA	29 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4624	TABLET	40 mg	ORAL	NDA	29 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4627	TABLET	20 mg	ORAL	NDA	29 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4627	TABLET	20 mg	ORAL	NDA	29 sections
vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	60505-4772	TABLET	10 mg	ORAL	NDA authorized generic	31 sections
vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	60505-4772	TABLET	10 mg	ORAL	NDA authorized generic	31 sections